Physiological FVIII clearance receptors

Physiological FVIII clearance receptors are a group of endocytic proteins responsible for the removal of coagulation Factor VIII (FVIII) from the bloodstream, thereby regulating its plasma concentration and half-life. The primary receptors involved in this process include the low-density lipoprotein receptor-related protein 1 (LRP1), the low-density lipoprotein receptor (LDLR), and the asialoglycoprotein receptor (ASGPR), along with others like the mannose receptor (CD206) and CLEC4M. These receptors recognize specific protein domains or carbohydrate structures on FVIII, often in a process modulated by von Willebrand factor (VWF), which normally protects FVIII from premature clearance by masking receptor-binding sites. In the context of Hemophilia A, these receptors are significant therapeutic targets because their activity limits the duration of effect for infused FVIII replacement therapies. Modern extended half-life (EHL) FVIII products are specifically engineered to bypass or reduce the affinity for these clearance receptors—through techniques such as PEGylation, Fc-fusion, or shielding with VWF domains—to decrease the frequency of infusions required for patients.

Other names

Factor VIII clearance receptorsFVIII catabolic receptorsFVIII clearance pathwayHepatic FVIII receptors

Extended half-life (EHL) Factor VIII products are engineered to reduce affinity for or evade these clearance receptors through chemical modifications like PEGylation, Fc-fusion, or protein engineering such as fusion with von Willebrand factor (VWF) domains, thereby prolonging the protein's circulation time and reducing infusion frequency.